EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

Who May Qualify: - Age ≥18 years. - diagnosed by tissue sample (biopsy-confirmed) advanced/metastatic solid tumor that is relapsed/refractory after standard therapy (or no standard therapy available). - tumors that can be measured on scans v1.1 (or iRECIST if applicable). - You should be able to carry out daily activities with 0 level of ability (ECOG 0)-1 (or 0-2 as allowed). - your organs (liver, kidneys, etc.) are working well enough based on blood tests (thresholds modeled on NK protocols): - platelet count at least 75,000/µL; blood count (hemoglobin) at least 9 g/dL; white blood cell count (ANC) at least 1,000/µL (unsupported by growth factors/transfusions as defined). - eGFR ≥ 60 mL/min/1.73m². - AST/ALT ≤ 3× ULN. - Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated). - LVEF ≥ 40% (by ECHO/MUGA/CMR). - If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids. Who Should NOT Join This Trial: - Pregnant or breastfeeding. - Any condition requiring systemic immunosuppression (e.g., \>5 mg prednisone/day or equivalent) during dosing window (topical/inhaled may be allowed). - Active autoimmune conditions (where your immune system attacks your own body) requiring systemic immunosuppression. - Uncontrolled bacterial, fungal, or viral infection. - Receipt of investigational agent within 28 days before first study drug. - Live vaccine within 6 weeks prior to lymphodepletion. - Known HIV positivity or active hepatitis B/C with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan). - Known allergy to investigational product components (example: albumin/human or DMSO). - Any medical/social condition likely to interfere with study compliance or increase risk. Always talk to your doctor about whether this trial is right for you.